News

Analysis of > 9,000 FDA reports highlights previously unrecognized adverse events, including myocardial stunning, nerve damage, and real-world drug ineffectiveness.

Manne-Goehler discusses a recent study highlighting the scope and scale at which GLP-1 receptor agonists can reduce obesity and its associated risks.

Investigators ranked the short-term effectiveness of 4 oral JAKis, upadacitinib, abrocitinib, baricitinib, and ivarmacitinib in moderate-to-severe atopic dermatitis.

The FDA has extended its review of the sNDA, delaying the previous January 13, 2026, PDUFA date, to April 13, 2026.

An FDA review found no increased risk of SI/B associated with the use of GLP-1 RA medications, including liraglutide, semaglutide, and tirzepatide.

Open-label RCT findings suggest a short-term, calorie-restrictive diet may be an effective intervention for mild and moderate Crohn’s disease.

This episode of Skin of Color Savvy was filmed on-site at the Skin of Color Society's 'Meeting the Challenge Summit' in Washington, DC.

The KAI 12L program is now cleared to determine short PR interval, atrial bigeminy, ventricular bigeminy, left axis deviation, and right axis deviation.

These recommendations simultaneously emphasize the efficacy of weight loss drugs and encourage incorporating lifestyle therapy on top of medication.

Neurolief’s physician-directed therapy brings supervised, noninvasive brain stimulation into the home for adults with MDD who have not responded to ≥ 1 antidepressant.

Investigators assessed the 72-week effectiveness of tralokinumab on 4 anatomical regions among patients with atopic dermatitis in real-world clinical practice.

The report details the disease burden, mortality, and quality of care trends for 5 major risk factors and the 5 leading causes of CVD death.

An audio recap of the top 5 stories in healthcare news from the week of 01/04-01/10.

This systematic search of databases was conducted to identify research evaluating drugs used for prurigo nodularis (PN).

In a multicenter analysis, ZEBRA, an AI-assisted pathology tool, showed high sensitivity and specificity for detecting Fabry nephropathy in renal biopsies.

Patients with idiopathic pulmonary fibrosis treated with the STAT3 inhibitor TTI-101 had greater reductions in lung fibrosis scores and IL-6 levels than placebo at 12 weeks.

Armstrong discusses the positive time-to-healing data from the phase 2 LEGenD-1 study, investigating anatomically targeted delivery of AMG0001.

Bristol Myers Squibb has reported positive results from the ongoing SCOUT-HCM trial, demonstrating mavacamten’s efficacy in reducing Valsalva LVOT.

A retrospective analysis links low pretransplant exercise tolerance with reduced skeletal muscle recovery and persistent sarcopenia risk after living donor kidney transplantation in CKD.

The NDA is supported by data from the phase 3 TRIUMpH clinical program and seeks approval for heartburn in NERD, healing of erosive esophagitis, and maintenance of healing.

In this retrospective single-center analysis, adult patients with moderate-to-severe atopic dermatitis treated with dupilumab were evaluated for super responder status.

Repeat monthly dosing of sustained-release lidocaine ST-01 met primary and secondary endpoints in phase 2 trial, delivering durable pain relief in men with chronic scrotal pain.

According to an announcement by parent company Medtronic, the MiniMed Go app is expected to launch in the spring of 2026.

The Q4 recap for cardiology spotlights major FDA decisions, key clinical trial updates, and more.

In her interview, Melinda Gooderham, MD, highlights the impact of recent topline findings on zasocitinib, a once-daily pill for adults with psoriasis.

Stay updated with the latest healthcare breakthroughs, including FDA approvals and other regulatory updates, in this week’s essential news roundup.

Rosenson explains the data gained from a terminated phase 2b trial, highlighting evinacumab’s potential as a triglyceride-lowering therapy.

In this analysis, the 12-month use of a home-use helmet-type LLLT device was evaluated among individuals with androgenetic alopecia (AGA).